Objective response and time to progression on sequential
treatment with sunitinib and sorafenib in metastatic renal cell
carcinoma

J 2012

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

BÜCHLER, Tomáš; Tomáš PAVLÍK; Zbyněk BORTLÍČEK; Alexandr POPRACH; Rostislav VYZULA et al.

Základní údaje

Originální název

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

Autoři

BÜCHLER, Tomáš; Tomáš PAVLÍK; Zbyněk BORTLÍČEK; Alexandr POPRACH; Rostislav VYZULA; Jitka ABRAHÁMOVÁ a Bohuslav MELICHAR

Vydání

Medical Oncology, 2012, 1357-0560

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.147

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00062519

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s12032-012-0293-x

UT WoS

000311513800046

Klíčová slova anglicky

Sunitinib; Sorafenib; Renal cell carcinoma; Response

Změněno: 22. 4. 2013 18:49, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to firstversus second TKI was observed (p\0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression- free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.

Citovat

BÜCHLER, Tomáš; Tomáš PAVLÍK; Zbyněk BORTLÍČEK; Alexandr POPRACH; Rostislav VYZULA; Jitka ABRAHÁMOVÁ a Bohuslav MELICHAR. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology. 2012, roč. 29, č. 5, s. 3321-3324. ISSN 1357-0560. Dostupné z: https://doi.org/10.1007/s12032-012-0293-x.

@article{1079905,
   author = {Büchler, Tomáš and Pavlík, Tomáš and Bortlíček, Zbyněk and Poprach, Alexandr and Vyzula, Rostislav and Abrahámová, Jitka and Melichar, Bohuslav},
   article_number = {5},
   doi = {https://doi.org/10.1007/s12032-012-0293-x},
   keywords = {Sunitinib; Sorafenib; Renal cell carcinoma; Response},
   language = {eng},
   issn = {1357-0560},
   journal = {Medical Oncology},
   title = {Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma},
   volume = {29},
   year = {2012}
}

TY  - JOUR
ID  - 1079905
AU  - Büchler, Tomáš - Pavlík, Tomáš - Bortlíček, Zbyněk - Poprach, Alexandr - Vyzula, Rostislav - Abrahámová, Jitka - Melichar, Bohuslav
PY  - 2012
TI  - Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma
JF  - Medical Oncology
VL  - 29
IS  - 5
SP  - 3321-3324
EP  - 3321-3324
SN  - 13570560
KW  - Sunitinib
KW  - Sorafenib
KW  - Renal cell carcinoma
KW  - Response
N2  - Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtained from a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to firstversus second TKI was observed (p\0.001). No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression- free survival times in the subgroup patients who discontinued treatment because of disease progression. In conclusion, the duration of response on first TKI is of limited value in selecting mRCC patients for sequential TKI therapy. There is a strong correlation between the types of tumour response on the first- versus the second TKI.
ER  -

BÜCHLER, Tomáš; Tomáš PAVLÍK; Zbyněk BORTLÍČEK; Alexandr POPRACH; Rostislav VYZULA; Jitka ABRAHÁMOVÁ a Bohuslav MELICHAR. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. \textit{Medical Oncology}. 2012, roč.~29, č.~5, s.~3321-3324. ISSN~1357-0560. Dostupné z: https://doi.org/10.1007/s12032-012-0293-x.

Přehled o publikaci